CAS 144875-48-9: Resiquimod
Description:Resiquimod is a synthetic imidazoquinoline compound that acts as an immune response modifier, primarily functioning as a toll-like receptor (TLR) 7 and TLR8 agonist. It is characterized by its ability to stimulate the innate immune system, leading to the activation of various immune cells, including dendritic cells and macrophages. This activation results in the production of pro-inflammatory cytokines and enhances both the humoral and cellular immune responses. Resiquimod is often explored for its potential therapeutic applications in treating viral infections, certain cancers, and skin conditions, such as actinic keratosis and superficial basal cell carcinoma. The compound is typically administered topically, and its formulation may include various excipients to enhance skin penetration and bioavailability. Due to its immunomodulatory effects, Resiquimod has been the subject of numerous clinical studies, highlighting its role in enhancing vaccine efficacy and its potential as an adjuvant in immunotherapy. Safety profiles indicate that it may cause local skin reactions, which are generally mild and transient.
Formula:C17H22N4O2
InChI:InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
InChI key:InChIKey=BXNMTOQRYBFHNZ-UHFFFAOYSA-N
SMILES:OC(C)(C)CN1C(=NC=2C(=NC=3C=CC=CC3C21)N)COCC
- Synonyms:
- 1-[4-Amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
- 1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-α,α-dimethyl-
- 4-Amino-2-(ethoxymethyl)-1-(2-hydroxyisobutyl)imidazo[4,5-c]quinoline
- 4-Amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol
- 4-Amino-2-(ethoxymethyl)-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol
- R-848
- Resimiquimod
- Resiquimod
- S-28463
- Vml-600
- See more synonyms